SAN DIEGO, Aug. 7 /PRNewswire/ -- ChemBridge Research Laboratories, Inc. (CRL) announced today that it has established an industry record in turn-around time for hit-to-lead follow-up libraries. Such ultra-fast hit-to-lead libraries are now produced in CRL's San Diego facilities in a matter of three to six days which enables critical acceleration of our clients' medicinal chemistry projects and sets a new industry benchmark. This state-of-the-art high-throughput chemistry technology was developed at CRL over the last seven years and refined in collaborations with Pfizer, Merck, AstraZeneca and others.
CRL's ultra-fast library production process is optimized at every step and includes: on-the-fly building block validation and protocol adjustment; one to three parallel synthesis steps across a very broad reaction range; high-throughput HPLC purification and LC/MS analysis; data processing; and robotic reformatting to ready-to-be-shipped custom plates/vials. The expertise, problem solving ability, and versatility of synthetic skills of CRL's chemists (the majority of whom are PhD's) also allow for rapid development of new parallel synthetic protocols and multi-step synthesis of intermediates and templates on-the-fly for the most challenging research-intensive hit-to-lead libraries.
"We are very pleased that our CRL chemists have been able to achieve speed and efficiency in hit-to-lead library production which even a year ago was not considered possible," said Eugene Vaisberg, Chairman and CEO of ChemBridge Corporation and CRL. "Their ability to produce and deliver high quality hit-to-lead libraries in less than a week continues the ChemBridge tradition of setting a gold standard in discovery chemistry outsourcing. It also offers a substantial competitive advantage for our clients allowing their precious medicinal chemistry resources to focus on their core expertise and to improve their hit-to-drug candidate success rate and timelines. This is of foremost importance now when research efficiency and productivity becomes the 'name of the game' for the pharmaceutical and biotech industry."
About ChemBridge Research Laboratories, Inc. (CRL)
ChemBridge Research Laboratories, Inc. (CRL), http://www.chembridgeresearch.com, is a San Diego based discovery chemistry CRO, which provides chemistry solutions for early stages of small molecule drug discovery. Founded in 2000 as a spin-off of ChemBridge Corporation, CRL has now become a center of excellence in high-throughput medicinal chemistry with a particular focus on ultra-fast hit-to-lead libraries. CRL's world-class research team has exceeded expectations in all its collaborations, including multi-year alliances with Pfizer, Merck, AstraZeneca and other major pharmaceutical and biotech companies.
About ChemBridge Corporation
ChemBridge Corporation, http://www.chembridge.com, is a leading global discovery chemistry CRO and screening compound library provider with an impeccable 15 year track record of quality and deliverability. ChemBridge is a San Diego based company which operates a state-of-the-art offshore discovery chemistry research site in Moscow, Russia. ChemBridge's CRO business includes multi-year strategic alliances with major pharmaceutical companies such as Pfizer, Merck, and AstraZeneca, as well as smaller research collaborations with mid-size pharmaceutical and biotech companies. Over 500 pharmaceutical and biotech companies and universities worldwide have also taken advantage of ChemBridge's portfolio of advanced discovery chemistry off-the-self products, including its library of 700,000 diverse drug-like small molecule screening compounds and 10,000 building blocks.
|SOURCE ChemBridge Research Laboratories, Inc.|
Copyright©2008 PR Newswire.
All rights reserved